Expression perception and timing in people with Parkinson’s Disease
Objective: To develop a paradigm to test whether the perception of mouth movements is improved when movements occur at a predictable point in time. In…Deep brain stimulation increases descending inhibitory control in a patient with Parkinson´s disease and pain
Objective: We present the first observation of deep brain stimulation (DBS) effects on spinal nociception as assessed by the nociceptive flection reflex (NFR) during DBS…Differential proteomic analysis of plasma exosomes in Parkinson disease associated with mutations in the GBA gene
Objective: To identify the protein changes and to search the potential biomarkers of PD among GBA mutation carriers. Background: Mutations in the GBA gene encoding glucocerebrosidase enzyme are the…In vivo synaptic density in parkinsonism
Objective: To provide first evidence of in vivo binding properties of the [18F]SynVesT-1 tracer (aka [18F]-SDM-8) for the quantification of synaptic density loss in a…Psychometric properties and construct validity of the Parkinson’s Disease-Cognitive Rating Scale (PD-CRS) in Colombia.
Objective: Assess the psychometric properties of PD-CRS in a Colombian population. Background: Cognitive impairment is frequent amongst people living with Parkinson’s disease: up to 40%…The Parkinson’s Incidence Cohorts Collaboration (PICC): an international collaboration of incident PD cohorts
Objective: To (i) identify all incidence cohorts of Parkinson’s disease (PD) with long-term follow up and (ii) pool data from these cohorts to study PD…Patients with Parkinson’s Disease Share a Unique Olfactory Perceptual Fingerprint
Objective: To explore potential olfactory biomarkers for early detection of Parkinson's disease Background: Although the olfactory decline in Parkinson’s disease (PD) precedes the motor symptoms…Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for the treatment of Parkinson’s Disease
Objective: To compare and contrast nilotinib and vodobatinib regarding efficacy, brain penetration, and safety. Background: Preclinical evidence suggests that c-Abl is critical for pathogenesis of…Longitudinal clinical and biomarkers characteristics of non-manifest LRRK2 G2019S carriers: The PPMI cohort
Objective: To examine 2-year longitudinal change in clinical, dopamine transporter (DAT) imaging and biofluid biomarkers in non-manifesting carriers (NMCs) of LRRK2 G2019S versus healthy controls…Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease: the PD COMM randomised controlled trial.
Objective: To evaluate the clinical effectiveness of two speech and language therapy (SLT) approaches compared to no SLT (control) for people with Parkinson’s disease (PD).…
- « Previous Page
- 1
- …
- 196
- 197
- 198
- 199
- 200
- …
- 338
- Next Page »